Equities

Jiangsu Hengrui Pharmaceuticals Co Ltd

600276:SHH

Jiangsu Hengrui Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)44.77
  • Today's Change-5.42 / -10.80%
  • Shares traded19.51m
  • 1 Year change-5.03%
  • Beta1.0814
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments20,84517,87118,697
Total Receivables, Net6,6819,0507,659
Total Inventory2,3142,4512,403
Prepaid expenses1,4471,5621,405
Other current assets, total--0.2524
Total current assets31,28730,93430,188
Property, plant & equipment, net6,9646,9996,725
Goodwill, net------
Intangibles, net3,3762,201702
Long term investments1,4511,5081,001
Note receivable - long term------
Other long term assets------
Total assets43,78542,37139,266
LIABILITIES
Accounts payable1,2701,4871,787
Accrued expenses152110181
Notes payable/short-term debt4101,709563
Current portion long-term debt/capital leases------
Other current liabilities, total721334871
Total current liabilities2,5543,6393,402
Total long term debt7599152
Total debt4851,808714
Deferred income tax8410025
Minority interest567589569
Other liabilities, total39119117
Total liabilities3,3194,5474,263
SHAREHOLDERS EQUITY
Common stock6,3796,3796,396
Additional paid-in capital3,0583,0203,356
Retained earnings (accumulated deficit)32,10228,81925,928
Treasury stock - common(1092)(398)(665)
Unrealized gain (loss)------
Other equity, total193.23(12)
Total equity40,46637,82435,003
Total liabilities & shareholders' equity43,78542,37139,266
Total common shares outstanding6,3556,3706,382
Treasury shares - common primary issue249.1714
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.